iConcept Press Logo
Email Password Remember me
Cervical, Breast and Prostate Cancer
Title
Cervical, Breast and Prostate Cancer
Editor
iConcept Press
Price
USD$109.99
ISBN
978-1-922227-86-7
Clicks
44601

Chapter 2

Cervical, Breast and Prostate Cancer

A Review of Update Clinical Results of Carbon Ion Radiotherapy for Uterine Cervical Cancer

by Masaru Wakatsuki, Shingo Kato, Kumiko Karasawa, Hirohiko Tsujii and Tadashi Kamada

Viewed: 1814

Abstract

Carbon ion beams offer improved dose distribution, resulting in the concentration of a sufficient dose within a target volume while minimizing the dose in surrounding normal tissues. Moreover, carbon ions possess a biological advantage due to their high relative biological effectiveness (RBE) in the Bragg Peak. A number of reports have demonstrated the favorable results of carbon ion radiotherapy (C-ion RT) in the treatment of several malignant tumors. As for clinical trials of C-ion RT for locally advanced cervical cancer, 5 have already been completed, and 2 are still ongoing. Between June 1995 and January 2012, 62 patients in 3 clinical trials were treated with C-ion RT for locally advanced squamous cell carcinoma of the uterine cervix. The numbers of patients with stage IIB, IIIB, and IVA disease were 14, 38, and 10, respectively. Median tumor size was 6.4 cm (range, 4.0–12.0 cm). Median overall treatment time was 36 days (range, 32 to 48 days). The 5-year overall survival rate and local control rate were 53.4% and 74.1%, respectively. Even though the tumors of our cases were bulky (median size, 6.4 cm) and 2 of the 3 trials were dose-escalation trials, the local control rate was favorable; nonetheless, distant metastases frequently occurred, and the 5-year overall survival rate was still considered unsatisfactory. C-ion RT for uterine adenocarcinoma has been targeted primarily at non-resectable tumors, and a total of 61 patients with locally advanced adenocarcinoma of the uterine cervix were enrolled in a dose-escalation trial between April 1998 and February 2010. Six of the 61 patients were subsequently disqualified and excluded from the analysis. The number of patients with stage IIB, IIIB, and IVA disease were 20, 33, and 2, respectively. Pelvic lymph node metastases were found in 25 of the patients. Median tumor size was 5.5 cm (range, 3.0-11.8 cm). The 5-year local control rate, local control rate including salvage surgery, and overall survival rate were 54.5%, 68.2%, and 38.1%, respectively. Although the number of patients in this study was small, the results support the need for further investigations to confirm the therapeutic efficacy. Hence, we are now conducting new clinical trials of C-ion RT with concurrent chemotherapy for locally advanced cervical cancer.

Author Details

Masaru Wakatsuki
Research Center for Charged Particle Therapy, National Institute of Radiological Sciences, Japan, Japan
Shingo Kato
Department of Radiation Oncology, Saitama Medical University International Medical Center, Japan, Japan
Kumiko Karasawa
Research Center for Charged Particle Therapy, National Institute of Radiological Sciences, Japan, Japan
Hirohiko Tsujii
Research Center for Charged Particle Therapy, National Institute of Radiological Sciences, Japan, Japan
Tadashi Kamada
Research Center for Charged Particle Therapy, National Institute of Radiological Sciences, Japan, Japan

Citation

Masaru Wakatsuki, Shingo Kato, Kumiko Karasawa, Hirohiko Tsujii and Tadashi Kamada. A Review of Update Clinical Results of Carbon Ion Radiotherapy for Uterine Cervical Cancer. In Cervical, Breast and Prostate Cancer. ISBN:978-1-922227-86-7. iConcept Press. 2014.

Download